BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Januvia (Sitagliptin) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Januvia (Sitagliptin)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07003542-295@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Januvia (Sitagliptin): Phase 2 readout est. (NCT07003542)
DESCRIPTION:Januvia (Sitagliptin)\, phase 2.\nStudy: A Phase 2 and Pharmaco
 dynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas\
 nEstimated primary completion: June 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/sitagliptin#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07003542
URL:https://assetmemo.bio/drug/sitagliptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07436663-295@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Januvia (Sitagliptin): Phase 4 readout est. (NCT07436663)
DESCRIPTION:Januvia (Sitagliptin)\, phase 4.\nStudy: Comparative Study Betw
 een (SGLT-2i) and (DPP-4i) in the Prevention of DIC\nEstimated primary com
 pletion: 1 November 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/sitagliptin#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07436663
URL:https://assetmemo.bio/drug/sitagliptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07634380-295@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20280410
DTEND;VALUE=DATE:20280411
SUMMARY:Januvia (Sitagliptin): Phase 1 readout est. (NCT07634380)
DESCRIPTION:Januvia (Sitagliptin)\, phase 1.\nStudy: Sitagliptin With Pembr
 o in RCC and Melanoma\nEstimated primary completion: 10 April 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/sitagliptin#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07634380
URL:https://assetmemo.bio/drug/sitagliptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07717242-295@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Januvia (Sitagliptin): Phase 2 readout est. (NCT07717242)
DESCRIPTION:Januvia (Sitagliptin)\, phase 2.\nStudy: Sun Yat-Sen Treatment 
 Strategy for Enhancing Response in Muscle-invasive Bladder Cancer\nEstimat
 ed primary completion: 30 June 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/sitagliptin#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07717242
URL:https://assetmemo.bio/drug/sitagliptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06587698-295@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Januvia (Sitagliptin): Phase na readout est. (NCT06587698)
DESCRIPTION:Januvia (Sitagliptin)\, phase na.\nStudy: Sitagliptin or BeiDou
 Gen Capsule Improve the Pregnancy Outcome in Patients with PCOS\nEstimated
  primary completion: 1 July 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/sitagliptin#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06587698
URL:https://assetmemo.bio/drug/sitagliptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07804381-295@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20290301
DTEND;VALUE=DATE:20290302
SUMMARY:Januvia (Sitagliptin): Phase 2 readout est. (NCT07804381)
DESCRIPTION:Januvia (Sitagliptin)\, phase 2.\nStudy: Disease-modifying Effi
 cacy of Sitagliptin Therapy in Early-stage Parkinson's Disease\nEstimated 
 primary completion: 1 March 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/sitagliptin#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07804381
URL:https://assetmemo.bio/drug/sitagliptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07541781-295@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20290611
DTEND;VALUE=DATE:20290612
SUMMARY:Januvia (Sitagliptin): Phase 1 readout est. (NCT07541781)
DESCRIPTION:Januvia (Sitagliptin)\, phase 1.\nStudy: Sitagliptin in Recurre
 nt/Progressive Grade 4 Glioma\nEstimated primary completion: 11 June 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/sitagliptin#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07541781
URL:https://assetmemo.bio/drug/sitagliptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07108985-295@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20290901
DTEND;VALUE=DATE:20290902
SUMMARY:Januvia (Sitagliptin): Phase 4 readout est. (NCT07108985)
DESCRIPTION:Januvia (Sitagliptin)\, phase 4\, Type 2 Diabetes.\nStudy: Effe
 ct of Add-on SGLT2i\, TZD\, or Combination Therapy in Type 2 Diabetes Pati
 ents on DPP4 Inhibitors\nEstimated primary completion: 1 September 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/sitagliptin#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07108985
URL:https://assetmemo.bio/drug/sitagliptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07365592-295@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Januvia (Sitagliptin): Phase 1/2 readout est. (NCT07365592)
DESCRIPTION:Januvia (Sitagliptin)\, phase 1/2.\nStudy: Neoadjuvant Chemothe
 rapy\, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC\nE
 stimated primary completion: 1 December 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/sitagliptin#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07365592
URL:https://assetmemo.bio/drug/sitagliptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07675174-295@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20300701
DTEND;VALUE=DATE:20300702
SUMMARY:Januvia (Sitagliptin): Phase 1/2 readout est. (NCT07675174)
DESCRIPTION:Januvia (Sitagliptin)\, phase 1/2.\nStudy: PTCy\, Bortezomib an
 d Sitagliptin for Prevention of GvHD Following Allogeneic HSCT\nEstimated 
 primary completion: 1 July 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/sitagliptin#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07675174
URL:https://assetmemo.bio/drug/sitagliptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06813014-295@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20311130
DTEND;VALUE=DATE:20311201
SUMMARY:Januvia (Sitagliptin): Phase 4 readout est. (NCT06813014)
DESCRIPTION:Januvia (Sitagliptin)\, phase 4.\nStudy: Pharmacogenetics of Re
 sponse to Sitagliptin (PRS)\nEstimated primary completion: November 2031. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/sitagliptin#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06813014
URL:https://assetmemo.bio/drug/sitagliptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
